CA-DNA-SCRIPT
16.9.2022 08:01:52 CEST | Business Wire | Press release
DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, won the Grand Prize Trophy at the 2022 Future Unicorns Awards, whose ceremony took place on September 15, 2022, at the Bourrienne Hotel (Paris). Of the 1400 French companies initially identified for consideration, a jury narrowed them down to 250 that met the criteria, from which DNA Script was selected as the Grand Prize winner.
"DNA Script is honored to receive the Grand Prize Trophy, which recognizes our business and innovation strategy. Biology holds such incredible promise to solve some of mankind’s biggest challenges, with applications not just across healthcare but also climate change, food and clean water supply, bio-engineered materials and environmentally friendly chemicals, DNA data storage, and so much more. DNA Script’s mission is to make it easy for researchers to print DNA to accelerate this scientific discovery and the coming bio-revolution,” said Xavier Godron, DNA Script co-founder and CTO, in accepting the award on behalf of the company and his co-founders Thomas Ybert, CEO, and Sylvain Gariel, COO. “We share this award with the entire DNA Script team, who invest in the company's success daily; with our investors, who have placed their trust in us since the company’s inception; and with our customers, who share our vision to accelerate discovery through direct access to in-house DNA printing. We thank the members of the jury as well as their partners Audacia, Caisse d'Epargne, Deloitte, Emlyon Business School, Euronext, Reputation Age and Scope Group for this distinction."
DNA Script won the Biotech and Medtech Future Unicorns Award in 2021, and since then has achieved several milestones. These include completing a $200 million Series C investment round and expanding its global presence in China, Hong Kong, India, Singapore, South Korea and Taiwan for the sale, distribution and support of its products through distribution agreements. Following the launch of the SYNTAX System, the first commercial product using Enzymatic DNA Synthesis targeted at genomics and molecular biology workflows, in 2021, the company continues to develop their technology and portfolio of products to address DNA supply bottlenecks in life science research, precision therapeutics, biodefense, clinical testing and DNA data storage. The company launched new products earlier this year that enable researchers to develop much more efficiently new diagnostic or research assays, for instance in infectious diseases, personalized oncology fields or spatial biology. Recently the company announced a continued collaboration with the French Defense Innovation Agency, in liaison with the French Armament General Directorate (DGA), to detect and diagnose new pathogens. This collaboration followed a disclosed partnership with Wellcome Leap to accelerate the development of RNA-based products, including messenger RNA vaccines.
The Future Unicorns Trophies aim to identify French companies with strong growth potential that in the next five years can be valued at more than €1 billion. Five sectors are studied, and seven prizes are awarded: BioTech and MedTech, e-Commerce and Advertising, GreenTech and Mobility, Industry 4.0 and SaaS, and AI and Big Data. The selected companies must meet various criteria, including having their headquarters in France, being <15 years old, having raised >€5 million since company inception and being an unlisted independent company, among others.
About DNA Script
Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, enabling this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy. www.dnascript.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005403/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Geoswift and SKUx Announce Strategic Partnership to Develop a First-of-Its-Kind Programmable Stablecoin Commerce Network29.6.2026 14:00:00 CEST | Press release
Bridging digital assets, traditional finance, enterprise treasury, and agentic commerce through global programmable money infrastructure Geoswift and SKUx announced a groundbreaking partnership to develop a next-generation programmable stablecoin commerce network. This strategic collaboration bridges digital assets, traditional finance, and real-world commerce at a global scale, representing a "one-of-one" opportunity by combining Geoswift's global infrastructure with SKUx's specialized item-level controls directly within point-of-sale (POS) systems. While enterprise stablecoin usage continues to accelerate globally, governments, enterprises, payment networks, and AI-driven commerce platforms are increasingly seeking programmable payment infrastructure that can bridge digital assets with real-world commerce. The innovation goes far beyond treasury management or even enabling consumers to spend stablecoins at retail locations. Instead, it unlocks true "programmable money" with embedded
Esri Sponsors Smithsonian Exhibition Showcasing Natural and Cultural Objects from All 50 States29.6.2026 14:00:00 CEST | Press release
From These Lands Exhibition Highlights Connections Between People, Place, and Natural World Through Physical Specimens and Digital Maps Esri is the lead sponsor of the Smithsonian's From These Lands exhibition and developed maps powered by ArcGIS and a digital companion to extend engagement beyond the museum. The exhibition features more than 600 specimens and cultural artifacts from all 50 states, Washington, DC, and US territories, drawn from the Smithsonian's National Museum of Natural History's collection of over 148 million objects. Designed around themes of connection, diversity, and discovery, the exhibit explores how landscapes, ecosystems, and cultural traditions shape one another across regions and time. Animated mapping experiences enable visitors to explore topography, biomes, geology, migration patterns, and watersheds, revealing relationships across the continent. ArcGIS StoryMaps transforms the physical exhibit into an accessible digital narrative, extending its reach to
Cartilage Tissue Engineering Heads to Orbit in NSF and NASA-supported Study at the International Space Station29.6.2026 14:00:00 CEST | Press release
UC Irvine researchers use single cell RNA sequencing to study cartilage tissue engineered in microgravity Researchers in the DELTAi Lab at the University of California, Irvine, working with NASA, are using Evercode Cell Fixation to preserve samples aboard the International Space Station as part of a study of cartilage tissue engineering in microgravity. The unprecedented work, part of a National Science Foundation (NSF)-funded grant led by Dr. Wendy Brown and Dr. Kyriacos Athanasiou, announced today by Parse Biosciences, aims to advance treatments for the hundreds of millions of people worldwide affected by cartilage injury. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629548658/en/ Rachel Nordberg, PhD, from the DELTAi Lab at UC Irvine, prepping the BioServe device before it goes into orbit. Cartilage injuries cause significant pain and disability, and the need for implants that can repair or regenerate damaged tissue
Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour29.6.2026 13:55:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen," SSE: 688796; HKEX: 02315) today announced that it has received a first-instance civil judgment from the Shanghai Intellectual Property Court. The court ruled that Biocytogen did not infringe the relevant patent rights asserted by the plaintiff, Harbour Antibodies BV ("Harbour"), and ordered the plaintiff to bear the litigation costs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629347368/en/ Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour The judgment marks a significant first-instance outcome in the litigation and further affirms the independent innovation and intellectual property compliance of Biocytogen's core technology platforms. It also provides greater clarity for existing and prospective partners evaluating the RenNano® platform, reinforcing confidence in the Company's technology platforms and long-term innovation capabi
MANE Selects Kinaxis to Strengthen Global Planning Capabilities29.6.2026 13:00:00 CEST | Press release
Kinaxis Maestro™ platform to provide the digital foundation to strengthen MANE’s global planning capabilities and support its continued planning transformation Kinaxis®(TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced that MANE, one of the top five leading organizations worldwide in the flavours and fragrances industry, has selected Kinaxis to modernize its planning capabilities as it accelerates global growth as part of a broader enterprise-wide transformation initiative. Headquartered in the south of France, with a significant global footprint spanning multiple regions and customers across international markets, MANE is known for its innovation, technical expertise and strong commitment to sustainability. The company is investing in more connected, end-to-end planning capabilities to support continued growth and increasing operational complexity worldwide. Following an extensive evaluation process with major competitors in the market, M
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom